Enveric Biosciences Inc vs Toyota Motor Corp — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Toyota Motor Corp trades at $189.35 (market cap $223.57B). The key difference: Toyota Motor Corp is far larger — about 36059.7× Enveric Biosciences Inc's market cap, and Toyota Motor Corp pays a 3.32% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TM | |
|---|---|---|
Market Cap | $6.20M | $223.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $248.29 |
52-Week Low | $1.27 | $166.50 |
Enterprise Value | $1.30M | $417.39B |
Dividend Yield | — | 3.32% |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Toyota Motor (TM) trades at $190.09, up 1.39% with bullish technical signals and strong fundamentals. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $7.57 exceeding expectations by 62%. Valuation remains attractive with P/E of 8.48 and P/B of 0.95, while revenue growth continues at $48.04T for 2025. Technical indicators show bullish moving averages and support at $189.
Outlook remains positive given strong hybrid vehicle demand and raised earnings guidance, though risks include China sales weakness and recall-related costs. Analyst consensus leans cautious with 62.5% hold ratings despite no sell recommendations. The stock presents value opportunity with solid cash flow generation and market leadership position.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →